Disorder of Transplanted Kidney
5
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
20.0%
1 terminated out of 5 trials
75.0%
-11.5% vs benchmark
40%
2 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant
Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
Plasma Marine n-3 Polyunsaturated Fatty Acids and Patient and Graft Survival
Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection